A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of CTO-IUSCC-0730 study is to assess the clinical efficacy of LY3214996 in
combination with abemaciclib at the recommended phase 2 dose of LY3214996 200 mg orally daily
and abemaciclib 150 mg orally twice daily. Patients will be treated until evidence of disease
progression, non-compliance with study protocol, unacceptable major toxicity, at subject's
own request for withdrawal, or if the study closes for any reason.